Von Willebrand disease (VWD) is the most common inherited bleeding disorder, with an estimated prevalence of 0.6 to 1.3%.1In patients with VWD, hemostasis is impaired due to deficiency or dysfunction of von Willebrand factor (VWF).1The disease shows great heterogeneity, with the severity of bleeding ranging from mild to very severe.2Replacement therapy with a VWF-containing concentrate is widely used to treat or prevent bleeds in people with VWD,3, 4with long-term prophylaxis recommended in patients with a history of frequent and severe bleeds.5 This evidence concerns the gene VWF and hemorrhagic disease.